Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-29

Clinical Trial Update: Trial of Pimasertib in Hematological Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial of pimasertib in acute myeloid leukemia and other hematologic neoplasms was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pimasertib (pimasertib)

Snippet

Sponsor: EMD Serono | Conditions: Leukemia, Myeloid, Acute, Hematologic Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2017-03-29